Kiniksa Pharmaceuticals International, Plc
A biopharmaceutical company that makes medicines for inflammatory diseases, including ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, a painful swelling of the sac around the heart. Kiniksa was founded in 2015 by a group of former colleagues from an earlier biotech firm who reunited to keep developing treatments for rare conditions. The name Kiniksa is an invented, distinctive-sounding corporate word with no traditional meaning.
Granted 88.6K · Bought 3.00M
Granted 1.53M · Sold 1.57M
Bought 69.4K
Bought 843.4K
Granted 13.8K · Sold 95.8K
Granted 536.9K · Sold 452.1K
Granted 193.1K · Sold 177.8K
Granted 227.0K · Sold 176.4K
Granted 563.1K · Sold 628.7K
Granted 22.0K
Granted 439.1K · Sold 406.8K
Granted 15.3K
Granted 15.3K
Granted 144.4K
Granted 123.6K · Sold 108.3K
Granted 245.1K · Sold 219.3K
Granted 7.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector · 17 transactions | — | 5.64M | 88.6K | 3.00M | — |
| Patel Sanj KCHAIRMAN & CEO, Director · 113 transactions | — | 1.93M | 1.53M | — | 1.57M |
| Chen Bihua +3 co-filersDirector, 10% owner, 10% owner · 2 transactions | — | 1.73Mas of May 2018 | — | 69.4K | — |
| Deerfield Management Company, L.P. (Series C) +4 co-filersReporting owner · 5 transactions | — | 991.9Kas of May 2018 | — | 843.4K | — |
| Mahoney Stephen F.President & COO · 1 transaction | — | 882.0Kas of May 2018 | — | — | — |
| Heberlig ChrisExec VP & CFO · 1 transaction | — | 593.7Kas of May 2018 | — | — | — |
| Boess Carsten10% owner · 1 transaction | — | 552.6Kas of May 2018 | — | — | — |
| Beetham Thomas W.EVP & Chief Legal Officer · 11 transactions | — | 414.2Kas of Feb 2021 | 13.8K | — | 95.8K |
| Paolini John F.CHIEF MEDICAL OFFICER · 94 transactions | — | 124.0K | 536.9K | — | 452.1K |
| Malley ThomasDirector · 15 transactions | — | 87.3K | 193.1K | — | 177.8K |
| Megna Michael RCHIEF ACCOUNTING OFFICER · 95 transactions | — | 27.4K | 227.0K | — | 176.4K |
| Tessari EbenCHIEF STRATEGY OFFICER · 114 transactions | — | 24.0K | 563.1K | — | 628.7K |
| Levy Richard SDirector · 9 transactions | — | 22.0K | 22.0K | — | — |
| Ragosa MarkCHIEF FINANCIAL OFFICER · 105 transactions | — | 16.2K | 439.1K | — | 406.8K |
| Cole G BradleyDirector · 4 transactions | — | 15.3K | 15.3K | — | — |
| McCain Tracey LDirector · 4 transactions | — | 15.3K | 15.3K | — | — |
| Popovits Kimberly JDirector · 7 transactions | — | 15.3K | 144.4K | — | — |
| Quart Barry DDirector · 29 transactions | — | 12.7K | 123.6K | — | 108.3K |
| Moat RossCHIEF OPERATING OFFICER · 75 transactions | — | 12.0K | 245.1K | — | 219.3K |
| Rizvi QasimChief Commercial Officer · 2 transactions | — | 7.3Kas of Dec 2020 | 7.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +75.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.